- Program funded by the Coalition for Epidemic Preparedness Innovations (CEPI)
- In partnership with EnsiliTech
Yellow Fever Virus (YFV) Program
Despite the effectiveness of the current YFV-17D vaccine, recent outbreaks in new regions highlight an urgent market need for additional vaccines, especially considering the YFV-17D’s limited supply and risk to immunocompromised and elderly individuals. Our company is developing an innovative YFV vaccine that aims to offer a safe and long-lasting immune response for all populations, including those vulnerable to the current vaccine’s risks. This initiative represents an opportunity to fill a significant gap in global health protection and vaccine availability.
Hantaan Virus Program
With Hantaan virus cases on the rise globally, leading to serious conditions such as Hantavirus Pulmonary Syndrome and Hemorrhagic Fever with Renal Syndrome, our aim is to address this unmet medical need. We are at the forefront of developing a vaccine for this deadly virus, which represents a substantial market opportunity, given the lack of any current commercial vaccine and the high fatality rate associated with the infection.
Our versatile technology platform, currently deployed against these imminent threats, has the built-in flexibility for expansion into broader medical applications, including pioneering treatments for cancer. This will deliver new treatment options for large patient populations and substantial growth opportunities for investors.